{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:13:49Z","timestamp":1777392829323,"version":"3.51.4"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Cutaneous and superficial fungal infections affecting the skin, nails, and hair of humans are caused primarily by dermatophytes of the genera\n            <jats:named-content content-type=\"genus-species\">Trichophyton<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">Epidermophyton<\/jats:named-content>\n            or by yeasts of the genera\n            <jats:named-content content-type=\"genus-species\">Candida<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">Malassezia.<\/jats:named-content>\n            Onychomycosis is a common fungal infection of the nail that frequently coexists with tinea pedis, the most prevalent mycotic skin infection. Efficacy rates for current topical onychomycosis therapies are hampered by low drug penetration across the nail plate, which is theoretically obviated with nitric oxide (NO)-based topical therapies. The Nitricil technology platform is comprised of polysiloxane-based macromolecules that stably release therapeutic levels of NO. In the reported studies, NVN1000, the lead candidate of the platform, was assessed for its spectrum of\n            <jats:italic>in vitro<\/jats:italic>\n            activity against a broad range of filamentous fungi and yeast species commonly associated with cutaneous fungal infections. Time-kill assays demonstrated that NVN1000 exhibited fungicidal activity as early as 4 h. Additionally, the penetration of several unique NVN1000 NO-releasing drug product formulations (gel, cream, and lacquer) was evaluated following a single topical application in an\n            <jats:italic>in vitro<\/jats:italic>\n            infected human nail assay, with all formulations showing similar inhibition of fungal growth. Repeated topical application in this model demonstrated that a lower-strength dose of NO could achieve the same efficacy as a higher-strength dose after 7 days. Together, these\n            <jats:italic>in vitro<\/jats:italic>\n            results demonstrate that NO-releasing treatments rapidly penetrate the nail plate and eradicate the fungal infection, representing promising novel topical therapies for the treatment of onychomycosis and other cutaneous fungal infections.\n          <\/jats:p>","DOI":"10.1128\/aac.01026-17","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T09:33:18Z","timestamp":1525944798000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["Nitric Oxide-Releasing Macromolecule Exhibits Broad-Spectrum Antifungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections"],"prefix":"10.1128","volume":"62","author":[{"given":"Nathan","family":"Stasko","sequence":"first","affiliation":[{"name":"Novan, Inc., Morrisville, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"McHale","sequence":"additional","affiliation":[{"name":"Novan, Inc., Morrisville, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley J.","family":"Hollenbach","sequence":"additional","affiliation":[{"name":"Novan, Inc., Morrisville, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Martin","sequence":"additional","affiliation":[{"name":"Novan, Inc., Morrisville, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Doxey","sequence":"additional","affiliation":[{"name":"Novan, Inc., Morrisville, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1542\/pir.33-4-e22"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1815"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70397-X"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78552-4"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02117-0"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2013.12088"},{"key":"e_1_3_2_8_2","first-page":"492","article-title":"Management of onychomycosis and co-existing tinea pedis","volume":"14","author":"Lipner SR","year":"2015","unstructured":"Lipner SR, Scher RK. 2015. Management of onychomycosis and co-existing tinea pedis. J Drugs Dermatol 14:492\u2013494.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_9_2","first-page":"10","article-title":"The role of topical antifungal therapy for onychomycosis and the emergence of newer agents","volume":"7","author":"Del Rosso JQ","year":"2014","unstructured":"Del Rosso JQ. 2014. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol 7(7):10\u201318.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.4.501"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.7547\/14-088"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00029.2006"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2008.08.002"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02659-15"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2672.2001.01291.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/jam.12047"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-4-458"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08063.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-016-0879-x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119473"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1004"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2005.08.003"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.16.8841"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2012.02.002"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.62.06.0009"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20901"},{"key":"e_1_3_2_27_2","first-page":"815","article-title":"The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials","volume":"13","author":"Gupta AK","year":"2014","unstructured":"Gupta AK, Elewski BE, Sugarman IL, Leda C, Kawabata H, Kang R, Pillai R, Olin JT, Watanabe S. 2014. The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials. J Drugs Dermatol 13:815\u2013820.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.010"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2016.1178277"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.149.s65.5.x"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja0674338"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp9002865"},{"key":"e_1_3_2_33_2","volume-title":"CLSI document M27-A2","author":"CLSI","year":"2002","unstructured":"CLSI. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd edition. CLSI document M27-A2. CLSI, Wayne, PA."},{"key":"e_1_3_2_34_2","volume-title":"CLSI document M38-A2","author":"CLSI","year":"2008","unstructured":"CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd edition. CLSI document M38-A2. CLSI, Wayne, PA."},{"key":"e_1_3_2_35_2","volume-title":"QuintilesIMS national prescription audit (Jan 2016\u2013Jan 2017)","author":"QuintilesIMS","year":"2017","unstructured":"QuintilesIMS. 2017. QuintilesIMS national prescription audit (Jan 2016\u2013Jan 2017). QuintilesIMS, Parsippany, NJ."},{"key":"e_1_3_2_36_2","volume-title":"ASTM International document E2783-11","author":"ASTM International","year":"2016","unstructured":"ASTM International. 2016. Standard test method for assessment of antimicrobial activity for water miscible compounds using a time-kill procedure. ASTM International document E2783-11. ASTM International, West Conshohocken, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01026-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01026-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:15:48Z","timestamp":1645478148000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01026-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1128\/AAC.01026-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01026-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"2017-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01026-17"}}